Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bumetanide

FDA-approved product (tablet, oral), marketed as Bumetanide, Bumex, Enbumyst.

Registered studies
49
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Bumetanide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Heart failure
  • Kidney disease
  • Nephrotic syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Loop Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae16.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bumetanide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bumetanide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

    NCT03296813 · start 2018-07-11

    Registered record
    Registry ID
    NCT03296813
    Conditions
    Heart Failure
    Interventions
    Torsemide; Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-11
    Completion
    2022-07-29
    Enrolment
    2,973

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionTorsemide; Furosemide
    PhasePhase 3
    Registry statusCompleted

  • A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

    NCT03156153 · start 2017-05-24

    Registered record
    Registry ID
    NCT03156153
    Conditions
    Autism Spectrum Disorder
    Interventions
    Bumetanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-05-24
    Completion
    2019-07-10
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder
    InterventionBumetanide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

    NCT03107416 · start 2017-04-05

    Registered record
    Registry ID
    NCT03107416
    Conditions
    Unresectable Hepatocellular Carcinoma
    Interventions
    Hepatic artery embolization (HAE); Bumetanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2017-04-05
    Completion
    2027-04-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnresectable Hepatocellular Carcinoma
    InterventionHepatic artery embolization (HAE); Bumetanide
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Diuretic/Cool Dialysate Trial

    NCT02593526 · start 2017-01

    Registered record
    Registry ID
    NCT02593526
    Conditions
    Chronic Kidney Insufficiency
    Interventions
    Bumetanide; Cool Dialysate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2017-01
    Completion
    2022-05-27
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Insufficiency
    InterventionBumetanide; Cool Dialysate
    PhaseNot applicable
    Registry statusTerminated

  • Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology

    NCT02947880 · start 2016-12

    Registered record
    Registry ID
    NCT02947880
    Conditions
    Autistic Disorder
    Interventions
    Bumetanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-12
    Completion
    2020-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutistic Disorder
    InterventionBumetanide; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Effects of Fluid Balance Control in Critically Ill Patients

    NCT02765009 · start 2016-06-01

    Registered record
    Registry ID
    NCT02765009
    Conditions
    Fluid Shifts; Critical Care
    Interventions
    diuretics; albumin; fluid restriction; renal replacement
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-06-01
    Completion
    2020-05-25
    Enrolment
    1,411

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFluid Shifts; Critical Care
    Interventiondiuretics; albumin; fluid restriction; renal replacement
    PhaseNot applicable
    Registry statusCompleted

  • Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

    NCT02546583 · start 2015-08-31

    Registered record
    Registry ID
    NCT02546583
    Conditions
    Heart Failure
    Interventions
    Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide); IV Chlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-08-31
    Completion
    2020-01-23
    Enrolment
    458

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionIncreased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide); IV Chlorothiazide
    PhasePhase 1
    Registry statusCompleted

  • Bumetanide in Hypokalaemic Periodic Paralysis

    NCT02582476 · start 2015-01

    Registered record
    Registry ID
    NCT02582476
    Conditions
    Hypokalemic Periodic Paralysis
    Interventions
    Bumetanide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-05-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypokalemic Periodic Paralysis
    InterventionBumetanide; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure

    NCT02288819 · start 2014-09

    Registered record
    Registry ID
    NCT02288819
    Conditions
    Heart Failure
    Interventions
    Weight monitoring; Loop diuretic downtitration
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2014-09
    Completion
    2016-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionWeight monitoring; Loop diuretic downtitration
    PhaseNot applicable
    Registry statusTerminated

  • Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure

    NCT01973335 · start 2013-11

    Registered record
    Registry ID
    NCT01973335
    Conditions
    Heart Failure
    Interventions
    Combination therapy with acetazolamide and low-dose loop diuretics; High-dose loop diuretics; Upfront therapy with oral spironolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-11
    Completion
    2017-10
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionCombination therapy with acetazolamide and low-dose loop diuretics; High-dose loop diuretics; Upfront therapy with oral spironolactone
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Drugs Administered to Children

    NCT03481881 · start 2013-08-14

    Registered record
    Registry ID
    NCT03481881
    Conditions
    Pediatric ALL
    Interventions
    Standard of care drug
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2013-08-14
    Completion
    2033-08-14
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric ALL
    InterventionStandard of care drug
    PhaseNot recorded
    Registry statusRecruiting

  • Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics

    NCT01457053 · start 2011-11

    Registered record
    Registry ID
    NCT01457053
    Conditions
    Acute Decompensated Heart Failure
    Interventions
    Loop diuretics (furosemide, torsemide, bumetanide); Ultrafiltration
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2013-05
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Decompensated Heart Failure
    InterventionLoop diuretics (furosemide, torsemide, bumetanide); Ultrafiltration
    PhaseNot applicable
    Registry statusTerminated

  • NEMO1:NEonatal Seizure Using Medication Off-patent

    NCT01434225 · start 2011-08

    Registered record
    Registry ID
    NCT01434225
    Conditions
    Neonatal Seizures
    Interventions
    Bumetanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-06
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Seizures
    InterventionBumetanide
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Bumetanide Versus Furosemide in Heart Failure

    NCT00372762 · start 2011-01

    Registered record
    Registry ID
    NCT00372762
    Conditions
    Heart Failure
    Interventions
    Furosemide; Bumetanide; furosemide; bumetanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2011-01
    Completion
    2013-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionFurosemide; Bumetanide; furosemide; bumetanide
    PhasePhase 3
    Registry statusWithdrawn

  • Efficiency of Bumetanide in Autistic Children

    NCT01078714 · start 2010-03

    Registered record
    Registry ID
    NCT01078714
    Conditions
    Autistics Children
    Interventions
    bumetanide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutistics Children
    Interventionbumetanide
    PhasePhase 3
    Registry statusCompleted